Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
Status:
Terminated
Trial end date:
2017-04-03
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to explore the effect of REGN2176-3 on the Early
Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in
participants with neovascular age-related macular degeneration (AMD), compared to
intravitreal aflibercept injection (IAI) monotherapy.
The secondary objectives of the study were the following:
- To explore the effect of 2 dose levels of IVT REGN2176-3 on anatomical changes of CNV in
participants with nAMD compared to IAI monotherapy (at week 12)
- To evaluate if short-term treatment with REGN2176-3 followed by IAI monotherapy offered
the same or additional benefit compared to continuous treatment with REGN2176-3. Also to
determine if there was benefit in initiating IAI treatment prior to REGN2176-3 compared
to continuous treatment with IAI.
- To assess the safety and tolerability of IVT REGN2176-3 in participants with nAMD